Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Citi
Healthtrust
Baxter
Fuji
Medtronic

Generated: September 24, 2019

DrugPatentWatch Database Preview

Patent: 5,403,484

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,403,484
Title: Viruses expressing chimeric binding proteins
Abstract:In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.
Inventor(s): Ladner; Robert C. (Ijamsville, MD), Guterman; Sonia K. (Belmont, MA), Roberts; Bruce L. (Milford, MA), Markland; William (Milford, MA), Ley; Arthur C. (Newton, MA), Kent; Rachel B. (Boxborough, MA)
Assignee: Protein Engineering Corporation (Cambridge, MA)
Application Number:08/009,319
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,403,484
Patent Claims:see list of patent claims

Details for Patent 5,403,484

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Try a Free Trial Protein Engineering Corporation (Cambridge, MA) 2012-04-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chubb
Cipla
Covington
Express Scripts
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.